Table 2.
Outcomes assessed from selected studies.
| S. No. | Study | Year of study | Condition diagnosed | Sensitivity | Specificity | Positive predictive value (PPV) | Negative predictive value (NPV) |
|---|---|---|---|---|---|---|---|
| 1 | de Groof et al. (2019) | 2019 | Barrett’s neoplasia | 95% | 85% | NA a | NA |
| 2 | van der Sommen et al. (2016) | 2015 | Barrette’s neoplasia | 86% | 87% | 50% | 50% |
| 3 | de Groof et al. (2020) | 2019 | Barrett’s neoplasia | 91% | 89% | NA | NA |
| 4 | Struyvenberg et al. (2021) | 2020 | Barrett’s neoplasia | 88% | 78% | NA | NA |
| 5 | Ghatwary et al. (2019) | 2019 | Early esophageal adenocarcinoma | 73.2% | 78.2% | NA | NA |
| 6 | Ebigbo et al. (2019) | 2019 | Esophageal adenocarcinoma | 97% | 88% | NA | NA |
| 7 | Xia et al. (2021) | 2018 | Barrett’s neoplasia | 90% | 80% | 89.2% | 98% |
| 8 | Ebigbo et al. (2020) | 2019 | Barrett’s neoplasia | 83.7% | 100% | NA | NA |
| 9 | Oh et al. (2021) | 2019 | Gastrointestinal stromal tumors | 100% | 85.7% | 95.2% | 100% |
| 10 | Yang et al. (2022) | 2020 | Gastrointestinal stromal tumors | 98% | 94.4% | 94.2% | 98.1% |
| 11 | Wang D. et al. (2021) | 2021 | Sepsis | 87% | 89% | NA | NA |
| 12 | Minoda et al. (2020) | 2020 | Gastrointestinal stromal tumors | 91.7% | 100% | 84.6% | 72.1% |
| 13 | Wang Y. K. et al. (2021) | 2021 | Barrett’s neoplasia | 96.2% | 70.4% | 92.7% | 82.6% |
| 14 | Cai et al. (2019) | 2019 | Esophageal adenocarcinoma | 97.8% | 85.4% | 86.4% | 97.6% |
| 15 | Okagawa et al. (2022) | 2019 | Esophageal adenocarcinoma | 97.4% | 99.4% | 92.5% | 98% |
| 16 | Guo et al. (2020) | 2019 | Esophageal adenocarcinoma | 98% | 95% | 40% | 62% |
| 17 | Johnsson et al. (2020) | 2020 | Cardiac arrest | 98% | 97% | NA | NA |
a
NA, not applicable as missing details from the papers.